These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9854489)

  • 1. Biomagnetic activity in ovarian lesions.
    Anastasiadis P; Anninos P; Kotini A; Limberis B; Galazios G
    Anticancer Res; 1998; 18(5B):3753-6. PubMed ID: 9854489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of non-linear analysis for differentiating the biomagnetic activity in ovarian lesions.
    Anninos PA; Anastasiadis P; Kotini A
    J Obstet Gynaecol; 1999 May; 19(3):280-5. PubMed ID: 15512296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis of prostate lesions with the use of biomagnetic measurements and non-linear analysis.
    Anninos P; Papadopoulos I; Kotini A; Adamopoulos A
    Urol Res; 2003 Mar; 31(1):32-6. PubMed ID: 12624661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions.
    Fujii S; Kakite S; Nishihara K; Kanasaki Y; Harada T; Kigawa J; Kaminou T; Ogawa T
    J Magn Reson Imaging; 2008 Nov; 28(5):1149-56. PubMed ID: 18972356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential diagnosis of breast lesions by use of biomagnetic activity and non-linear analysis.
    Anninos PA; Kotini A; Koutlaki N; Adamopoulos A; Galazios G; Anastasiadis P
    Eur J Gynaecol Oncol; 2000; 21(6):591-5. PubMed ID: 11214617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
    Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
    Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Probability of malignant degeneration of ovarian tumors. Clinical study on the probability of malignant degeneration].
    Pfleiderer VA; Wipprecht KG; Ritzmann H; Tan TH
    Fortschr Med; 1976 Jan; 94(2):81-8. PubMed ID: 955547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of beta 2 microglobulin in malignant tumors of the ovaries].
    Kudela M; Fischerová E; Hansmanová L
    Cesk Gynekol; 1989 Jun; 54(5):341-4. PubMed ID: 2676201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
    Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of benign and malignant tumor of the ovary].
    Dias MF; Pereira HS; Sousa LA; Torgal IR; De Oliveira CF
    Acta Med Port; 1997 Oct; 10(10):653-7. PubMed ID: 9477588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review.
    Bazot M; Daraï E; Nassar-Slaba J; Lafont C; Thomassin-Naggara I
    J Comput Assist Tomogr; 2008; 32(5):712-23. PubMed ID: 18830100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triage of ovarian masses.
    Chia YN; Marsden DE; Robertson G; Hacker NF
    Aust N Z J Obstet Gynaecol; 2008 Jun; 48(3):322-8. PubMed ID: 18532966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomagnetism in gynaecologic oncology. Our experience in Greece.
    Kotini A; Anastasiadis AN; Koutlaki N; Tamiolakis D; Anninos P; Anastasiadis P
    Eur J Gynaecol Oncol; 2006; 27(6):594-6. PubMed ID: 17290589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of aspiration cytology of ovarian masses with histopathological correlation.
    Sood T; Handa U; Mohan H; Goel P
    Cytopathology; 2010 Jun; 21(3):176-85. PubMed ID: 19500123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Magnetic resonance tomography of ovarian tumors].
    Hamm B; Römer T; Albig M; Felix R; Wolf KJ
    Rofo; 1987 Apr; 146(4):429-38. PubMed ID: 3033768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.